Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Treatment of Philadelphia-negative Myeloproliferative Neoplasms in Accelerated/Blastic Phase with Azacytidine. Clinical Results and Identification of Prognostic Factors.

Andriani A, Elli E, Trapè G, Villivà N, Fianchi L, Di Veroli A, Niscola P, Centra A, Anaclerico B, Montanaro G, Martini V, Aroldi A, Carmosino I, Voso MT, Breccia M, Montanaro M, Foà R, Latagliata R.

Hematol Oncol. 2019 May 3. doi: 10.1002/hon.2635. [Epub ahead of print]

PMID:
31050810
2.

Could haemochromatosis (HFE) gene mutations affect response to iron chelation in myelodysplastic syndrome? - Response to Lucijanic and Kusec.

Fabiani E, Valentini L, Cilloni D, Voso MT.

Br J Haematol. 2019 May 1. doi: 10.1111/bjh.15938. [Epub ahead of print] No abstract available.

PMID:
31044416
3.

Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.

Faraoni I, Giansanti M, Voso MT, Lo-Coco F, Graziani G.

Biochem Pharmacol. 2019 Apr 24. pii: S0006-2952(19)30154-6. doi: 10.1016/j.bcp.2019.04.019. [Epub ahead of print] Review.

PMID:
31028744
4.

Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations.

Gurnari C, Lombardi AM, Cosi E, Biagetti G, Buccisano F, Franceschini L, Di Veroli A, Falconi G, Fabiani E, Cantonetti M, Nasso D, Lo-Coco F, Randi ML, Voso MT.

Br J Haematol. 2019 Apr 23. doi: 10.1111/bjh.15931. [Epub ahead of print] No abstract available.

PMID:
31016714
5.

Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.

Alfonso V, Iaccarino L, Ottone T, Cicconi L, Lavorgna S, Divona M, Cairoli R, Cristiano A, Ciardi C, Travaglini S, Falconi G, Hasan SK, Venditti A, Arcese W, Voso MT, Lo-Coco F.

Leukemia. 2019 Jan 16. doi: 10.1038/s41375-018-0298-3. [Epub ahead of print] No abstract available.

PMID:
30651632
6.

PML/RARA inhibits expression of HSP90 and its target AKT.

Piredda ML, Gaur G, Catalano G, Divona M, Banella C, Travaglini S, Puzzangara MC, Voso MT, Lo-Coco F, Noguera NI.

Br J Haematol. 2019 Mar;184(6):937-948. doi: 10.1111/bjh.15715. Epub 2018 Dec 9.

PMID:
30536958
7.

Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome.

Del Principe MI, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A, Consalvo MI, Paterno G, Sarlo C, De Bellis E, Zizzari A, De Angelis G, Fraboni D, Divona M, Voso MT, Sconocchia G, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Semin Hematol. 2018 Oct;55(4):209-214. doi: 10.1053/j.seminhematol.2018.02.006. Epub 2018 Feb 21. Review.

PMID:
30502849
8.

The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.

Spinello I, Saulle E, Quaranta MT, Pasquini L, Pelosi E, Castelli G, Ottone T, Voso MT, Testa U, Labbaye C.

Haematologica. 2019 May;104(5):973-985. doi: 10.3324/haematol.2018.199661. Epub 2018 Nov 22.

9.

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.

Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, Oliva EN, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P.

Blood Rev. 2019 Mar;34:16-25. doi: 10.1016/j.blre.2018.10.002. Epub 2018 Oct 28. Review.

PMID:
30448050
10.

Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia.

Iaccarino L, Divona M, Ottone T, Cicconi L, Lavorgna S, Ciardi C, Alfonso V, Travaglini S, Facchini L, Cimino G, Di Bona E, Voso MT, Lo-Coco F.

Genes Chromosomes Cancer. 2019 Jan;58(1):60-65. doi: 10.1002/gcc.22708. Epub 2018 Dec 4.

PMID:
30421475
11.

Molecular Expression of Bone Marrow Angiogenic Factors, Cell-Cell Adhesion Molecules and Matrix-Metallo-Proteinases in Plasmacellular Disorders: a Molecular Panel to İnvestigate Disease Progression.

Rapanotti MC, Franceschini L, Viguria TMS, Ialongo C, Fraboni D, Cerretti R, De Angelis G, Pupo L, Rizzo M, Cantonetti M, Postorino M, Voso MT, Lo-Coco F.

Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018059. doi: 10.4084/MJHID.2018.059. eCollection 2018. No abstract available.

12.

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Fabiani E, Calabrese C, Niscola P, Balleari E, Molteni A, Finelli C, Falconi G, Fenu S, Fianchi L, Criscuolo M, Salvi F, Lavorgna S, Buccisano F, Maurillo L, Lo Coco F, Cilloni D, Voso MT.

Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15655. [Epub ahead of print] No abstract available.

PMID:
30407614
13.

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.

Falconi G, Fabiani E, Piciocchi A, Criscuolo M, Fianchi L, Lindfors Rossi EL, Finelli C, Cerqui E, Ottone T, Molteni A, Parma M, Santarone S, Candoni A, Sica S, Leone G, Lo-Coco F, Voso MT.

Leukemia. 2019 Mar;33(3):785-790. doi: 10.1038/s41375-018-0284-9. Epub 2018 Oct 5. No abstract available.

PMID:
30291338
14.

Therapy-related myeloid neoplasms: clinical perspectives.

Fianchi L, Criscuolo M, Fabiani E, Falconi G, Maraglino AME, Voso MT, Pagano L.

Onco Targets Ther. 2018 Sep 17;11:5909-5915. doi: 10.2147/OTT.S101333. eCollection 2018. Review.

15.

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.

Gurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, Fianchi L, Criscuolo M, Sarlo C, Romano A, Falconi G, Niscola P, Di Veroli A, Breccia M, Piccioni A, Aloe-Spiriti MA, Lo-Coco F, Voso MT; GROM-L (Gruppo Romano-Laziale MDS); GROM-L (Gruppo Romano-Laziale MDS).

Leuk Res. 2018 Aug;71:89-91. doi: 10.1016/j.leukres.2018.07.002. Epub 2018 Jul 10. No abstract available.

PMID:
30029156
16.

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.

Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, Diverio D, Rizzo M, Ottone T, Iaccarino L, Alfonso V, Foa R, Voso MT, Lo-Coco F.

Ann Hematol. 2018 Oct;97(10):1797-1802. doi: 10.1007/s00277-018-3400-z. Epub 2018 Jun 27.

PMID:
29951912
17.

Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Spagnoli A, Voso MT, Fianchi L, Papayannidis C, Gaidano GL, Breccia M, Musto P, De Bellis E, Del Principe MI, Lunghi M, Lessi F, Martinelli G, Venditti A.

Ann Hematol. 2018 Oct;97(10):1767-1774. doi: 10.1007/s00277-018-3374-x. Epub 2018 Jun 10.

PMID:
29947973
18.

The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation.

Faraoni I, Aloisio F, De Gabrieli A, Consalvo MI, Lavorgna S, Voso MT, Lo-Coco F, Graziani G.

Cancer Lett. 2018 Jun 1;423:127-138. doi: 10.1016/j.canlet.2018.03.008. Epub 2018 Mar 8.

PMID:
29526802
19.

Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.

Buccisano F, Maurillo L, Del Principe MI, Di Veroli A, De Bellis E, Biagi A, Zizzari A, Rossi V, Rapisarda V, Amadori S, Voso MT, Lo-Coco F, Arcese W, Venditti A.

Expert Rev Hematol. 2018 Apr;11(4):307-313. doi: 10.1080/17474086.2018.1447378. Epub 2018 Mar 7. Review.

PMID:
29495904
20.

Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia.

Gurnari C, Panetta P, Fabiani E, Nardone AM, Postorivo D, Falconi G, Franceschini L, Rizzo M, Rapisarda VM, De Bellis E, Lo-Coco F, Voso MT.

Mol Clin Oncol. 2018 Mar;8(3):463-465. doi: 10.3892/mco.2017.1543. Epub 2017 Dec 29.

21.

Longitudinal detection of DNMT3AR882H transcripts in patients with acute myeloid leukemia.

Ottone T, Alfonso V, Iaccarino L, Hasan SK, Mancini M, Divona M, Lavorgna S, Cicconi L, Panetta P, Maurillo L, Del Principe MI, Irno Consalvo M, Franceschini L, Angelini DF, Battistini L, Guerrera G, De Bardi M, Fabiani E, Falconi G, Arcese W, Amadori S, Buccisano F, Venditti A, Voso MT, Lo-Coco F.

Am J Hematol. 2018 May;93(5):E120-E123. doi: 10.1002/ajh.25061. Epub 2018 Feb 24. No abstract available.

22.

Progress and criticalities in the management of acute promyelocytic leukemia.

Lo-Coco F, Cicconi L, Voso MT.

Oncotarget. 2017 Nov 12;8(59):99221-99222. doi: 10.18632/oncotarget.22385. eCollection 2017 Nov 21. No abstract available.

23.

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.

Visani G, Loscocco F, Ruzzo A, Galimberti S, Graziano F, Voso MT, Giacomini E, Finelli C, Ciabatti E, Fabiani E, Barulli S, Volpe A, Magro D, Piccaluga P, Fuligni F, Vignetti M, Fazi P, Piciocchi A, Gabucci E, Rocchi M, Magnani M, Isidori A.

Pharmacogenomics J. 2018 May 22;18(3):444-449. doi: 10.1038/tpj.2017.48. Epub 2017 Dec 5.

PMID:
29205204
24.

The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia.

Fabiani E, Falconi G, Noguera NI, Saulle E, Cicconi L, Divona M, Banella C, Picardi A, Cerio AM, Boe L, Sanchez M, Pelosi E, Testa U, Lo-Coco F, Voso MT.

Oncotarget. 2017 Sep 20;8(48):84074-84085. doi: 10.18632/oncotarget.21101. eCollection 2017 Oct 13.

25.

Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.

Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S.

Leuk Res. 2017 Nov;62:108-115. doi: 10.1016/j.leukres.2017.10.001. Epub 2017 Oct 5. Review.

PMID:
29054020
26.

Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Iaccarino L, Ottone T, Hasan SK, Divona M, Cicconi L, Lavorgna S, Alfonso V, Basso G, Barragán E, Bocchia M, Rego EM, Grimwade D, Voso MT, Lo-Coco F.

Leuk Lymphoma. 2018 May;59(5):1268-1270. doi: 10.1080/10428194.2017.1369067. Epub 2017 Aug 24. No abstract available.

PMID:
28838264
27.

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

Mayer F, Faglioni L, Agabiti N, Fenu S, Buccisano F, Latagliata R, Ricci R, Spiriti MAA, Tatarelli C, Breccia M, Cimino G, Fianchi L, Criscuolo M, Gumenyuk S, Mancini S, Maurillo L, Nobile C, Niscola P, Piccioni AL, Tafuri A, Trapè G, Andriani A, De Fabritiis P, Voso MT, Davoli M, Zini G.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017046. doi: 10.4084/MJHID.2017.046. eCollection 2017.

28.

Treatment of Low-Blast Count AML using Hypomethylating Agents.

De Bellis E, Fianchi L, Buccisano F, Criscuolo M, Maurillo L, Cicconi L, Brescini M, Del Principe MI, Di Veroli A, Venditti A, Amadori S, Arcese W, Lo-Coco F, Voso MT.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017045. doi: 10.4084/MJHID.2017.045. eCollection 2017. Review.

29.

High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.

Noguera NI, Pelosi E, Angelini DF, Piredda ML, Guerrera G, Piras E, Battistini L, Massai L, Berardi A, Catalano G, Cicconi L, Castelli G, D'Angiò A, Pasquini L, Graziani G, Fioritoni G, Voso MT, Mastrangelo D, Testa U, Lo-Coco F.

Oncotarget. 2017 May 16;8(20):32550-32565. doi: 10.18632/oncotarget.15925.

30.

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A.

Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17.

PMID:
28419408
31.

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S.

Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154.

32.

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A.

Leukemia. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21.

33.

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.

Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3.

PMID:
28162984
34.

Clonal evolution in therapy-related neoplasms.

Fabiani E, Falconi G, Fianchi L, Criscuolo M, Ottone T, Cicconi L, Hohaus S, Sica S, Postorino M, Neri A, Lionetti M, Leone G, Lo-Coco F, Voso MT.

Oncotarget. 2017 Feb 14;8(7):12031-12040. doi: 10.18632/oncotarget.14509.

35.

Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Picardi A, Cerretti R, Cudillo L, De Angelis G, Sarlo C, Cefalo M, Ditto C, Di Veroli A, Mariotti B, Nasso D, De Bellis E, Del Poeta G, Voso MT, Sconocchia G, Lo Coco F, Arcese W, Amadori S, Venditti A.

Bone Marrow Transplant. 2017 Mar;52(3):473-475. doi: 10.1038/bmt.2016.308. Epub 2016 Dec 12. No abstract available.

PMID:
27941782
36.

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Del Principe MI, Buccisano F, Maurillo L, Sconocchia G, Cefalo M, Consalvo MI, Sarlo C, Conti C, De Santis G, De Bellis E, Di Veroli A, Palomba P, Attrotto C, Zizzari A, Paterno G, Voso MT, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016052. eCollection 2016. Review.

37.

PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.

Noguera NI, Piredda ML, Taulli R, Catalano G, Angelini G, Gaur G, Nervi C, Voso MT, Lunardi A, Pandolfi PP, Lo-Coco F.

Oncotarget. 2016 Oct 11;7(41):66386-66397. doi: 10.18632/oncotarget.11964.

38.

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.

Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubezio M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Pozzi S, Luchetti S, Pezzetti L, Catricalà S, Milanesi C, Riva A, Bruno B, Ciceri F, Bonifazi F, Bellazzi R, Papaemmanuil E, Santoro A, Alessandrino EP, Rambaldi A, Cazzola M.

J Clin Oncol. 2016 Oct 20;34(30):3627-3637. doi: 10.1200/JCO.2016.67.3616.

39.

Panobinostat for the treatment of acute myelogenous leukemia.

Morabito F, Voso MT, Hohaus S, Gentile M, Vigna E, Recchia AG, Iovino L, Benedetti E, Lo-Coco F, Galimberti S.

Expert Opin Investig Drugs. 2016 Sep;25(9):1117-31. doi: 10.1080/13543784.2016.1216971. Epub 2016 Aug 8. Review.

PMID:
27485472
40.
41.

PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.

Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S, Alfonso V, Paoloni F, Piciocchi A, Avvisati G, Ferrara F, Di Bona E, Albano F, Breccia M, Cerqui E, Sborgia M, Kropp MG, Santoro A, Levis A, Sica S, Amadori S, Voso MT, Mandelli F, Lo-Coco F.

Leukemia. 2016 Oct;30(10):1987-1992. doi: 10.1038/leu.2016.122. Epub 2016 May 2.

PMID:
27133819
42.

Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.

Buccisano F, Piccioni AL, Nobile C, Criscuolo M, Niscola P, Tatarelli C, Fianchi L, Villivà N, Neri B, Carmosino I, Gumenyuk S, Mancini S, Voso MT, Maurillo L, Breccia M, Zini G, Venditti A, Fenu S, Spiriti MA, Latagliata R; GROM (Gruppo Romano Mielodisplasie).

Ann Hematol. 2016 Jun;95(7):1059-65. doi: 10.1007/s00277-016-2667-1. Epub 2016 Apr 19.

PMID:
27091349
43.

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F.

J Clin Oncol. 2016 Mar 20;34(9):972-9. doi: 10.1200/JCO.2015.64.0060. Epub 2016 Jan 25.

44.

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.

Roboz GJ, Montesinos P, Selleslag D, Wei A, Jang JH, Falantes J, Voso MT, Sayar H, Porkka K, Marlton P, Almeida A, Mohan S, Ravandi F, Garcia-Manero G, Skikne B, Kantarjian H.

Future Oncol. 2016 Feb;12(3):293-302. doi: 10.2217/fon.15.326. Epub 2016 Jan 19.

45.

CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.

Cuccaro A, Annunziata S, Cupelli E, Martini M, Calcagni ML, Rufini V, Giachelia M, Bartolomei F, Galli E, D'Alò F, Voso MT, Leone G, Giordano A, Larocca LM, Hohaus S.

Cancer Med. 2016 Mar;5(3):398-406. doi: 10.1002/cam4.585. Epub 2016 Jan 13.

46.

Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.

Iaccarino L, Ottone T, Divona M, Cicconi L, Cairoli R, Voso MT, Lo-Coco F.

Br J Haematol. 2016 Mar;172(6):909-13. doi: 10.1111/bjh.13910. Epub 2016 Jan 5. Erratum in: Br J Haematol. 2016 Jul;174(2):335.

PMID:
26728337
47.

An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome.

Martini M, Capodimonti S, Iachininoto MG, Cocomazzi A, Nuzzolo ER, Voso MT, Teofili L, Larocca LM.

Blood Cancer J. 2015 Nov 27;5:e370. doi: 10.1038/bcj.2015.97. No abstract available.

48.

Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.

Falconi G, Fabiani E, Fianchi L, Criscuolo M, Raffaelli CS, Bellesi S, Hohaus S, Voso MT, D'Alò F, Leone G.

Exp Hematol. 2016 Jan;44(1):75-83.e1-4. doi: 10.1016/j.exphem.2015.10.005. Epub 2015 Oct 28.

PMID:
26521017
49.

Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.

Tisi MC, Cupelli E, Santangelo R, Maiolo E, Alma E, Giachelia M, Martini M, Bellesi S, D'Alò F, Voso MT, Pompili M, Leone G, Larocca LM, Hohaus S.

Leuk Lymphoma. 2016;57(3):628-34. doi: 10.3109/10428194.2015.1072766. Epub 2015 Oct 12.

PMID:
26458141
50.

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.

Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F.

Lancet Oncol. 2015 Nov;16(15):1506-1514. doi: 10.1016/S1470-2045(15)00206-5. Epub 2015 Sep 21.

PMID:
26404501

Supplemental Content

Loading ...
Support Center